From the Research
Efficacy of GLP-1 in Type 1 Diabetes Mellitus
- GLP-1 receptor agonists (GLP-1 RAs) have been studied as a potential adjunctive treatment for Type 1 Diabetes Mellitus (T1DM) 1, 2, 3, 4
- Studies have shown that GLP-1 RAs can improve glycemic control, reduce insulin doses, and promote weight loss in patients with T1DM 1, 2, 4
- The use of GLP-1 RAs in T1DM has been associated with a low risk of hypoglycemia and diabetic ketoacidosis 2, 3
Patient Selection for GLP-1 Therapy
- Patients with T1DM who may benefit from GLP-1 RA therapy include those with detectable C-peptide, overweight or obese individuals, and those who cannot achieve glycemic goals without hypoglycemia 2, 4
- GLP-1 RAs may be particularly useful for patients with T1DM who are experiencing adverse effects from insulin therapy or who require high insulin doses 1, 2
Safety and Tolerability of GLP-1 RAs
- GLP-1 RAs have been shown to be well-tolerated in patients with T1DM, with mostly gastrointestinal adverse effects that are mild and transient 1, 2
- The risk of severe hypoglycemia and diabetic ketoacidosis is not significantly increased with GLP-1 RA therapy in T1DM 2, 3
Future Directions for Research
- Further studies are needed to evaluate the long-term efficacy and safety of GLP-1 RAs in T1DM, as well as their potential impact on microvascular and macrovascular complications 2, 4
- Research is also needed to determine the optimal patient selection criteria and treatment regimens for GLP-1 RA therapy in T1DM 4